dc.contributor.author | Akdeniz, Cansu Selcan | |
dc.contributor.author | Cevik, Mehtap | |
dc.contributor.author | Canbolat, Ismail Polat | |
dc.contributor.author | Yurdakul, Selen | |
dc.contributor.author | Cagatay, Penbe | |
dc.contributor.author | Ciftci, Cavlan | |
dc.contributor.author | Karaalp, Atila | |
dc.date.accessioned | 2021-06-10T19:38:38Z | |
dc.date.available | 2021-06-10T19:38:38Z | |
dc.date.issued | 2020 | |
dc.identifier.issn | 1479-6678 | |
dc.identifier.issn | 1744-8298 | |
dc.identifier.uri | https://doi.oeg/10.2217/fca-2020-0027 | |
dc.identifier.uri | http://hdl.handle.net/11446/4392 | |
dc.description | Karaalp, Atila/0000-0003-3382-9483 | en_US |
dc.description | PubMed: 32583677 | en_US |
dc.description | WOS:000614216900012 | en_US |
dc.description.abstract | Aim: Our aim was to examine the effect of CYP2C9 and VKORC1 polymorphisms on warfarin dose requirements in Turkish patients. Materials & methods: 24 warfarin prescribed patients were included and analyzed for eight VKORC1 and 6 CYP2C9 polymorphisms in the study. Results: Patients with CYP2C9 *1/*1 and VKORC1 -1639 GG and GA genotypes required higher warfarin doses in comparison to wild type VKORC1 genotype. Patients with CYP2C9 *1/*3 and VKORC1 -1639 GG genotypes simultaneously, required the lowest dose of warfarin (4.64 mg/day). Patients with CYP2C9 *1/*1 and VKORC1 9041 AA genotype were found to require higher warfarin doses. Conclusion: Our results provide additional evidence to support the hypothesis that CYP2C9 *2, *3, VKORC1 9041 G > A polymorphisms explain considerable proportion of inter-individual variability in warfarin dose requirement. | en_US |
dc.description.sponsorship | Istanbul Development AgencyTurkiye Cumhuriyeti Kalkinma Bakanligi [TR10/16/YNY/0030] | en_US |
dc.description.sponsorship | This study was supported by Istanbul Development Agency, Project No. TR10/16/YNY/0030. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Future Medicine Ltd | en_US |
dc.identifier.doi | 10.2217/fca-2020-0027 | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | 9041 G > A | en_US |
dc.subject | CYP2C9 | en_US |
dc.subject | pharmacogenetics | en_US |
dc.subject | VKORC1 | en_US |
dc.subject | warfarin | en_US |
dc.title | The effects of CYP2C9 and VKORC1 gene polymorphisms on warfarin maintenance dose in Turkish cardiac patients | en_US |
dc.type | article | en_US |
dc.relation.journal | Future Cardiology | en_US |
dc.department | [0-Belirlenecek] | en_US |
dc.identifier.issue | 6 | en_US |
dc.identifier.volume | 16 | en_US |
dc.identifier.startpage | 645 | en_US |
dc.identifier.endpage | 654 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.institutionauthor | [0-Belirlenecek] | |
dc.department-temp | [Akdeniz, Cansu Selcan; Canbolat, Ismail Polat; Yurdakul, Selen; Ciftci, Cavlan] Demiroglu Bilim Univ, Fac Med, Dept Cardiol, Istanbul, Turkey; [Cevik, Mehtap; Susleyici, Belgin] Marmara Univ, Fac Sci & Letters, Dept Mol Biol, Istanbul, Turkey; [Cagatay, Penbe] Istanbul Univ Cerrahpasa, Dept Med Serv & Tech, Vocat Sch Hlth Serv, Istanbul, Turkey; [Karaalp, Atila] Marmara Univ, Sch Med, Dept Med Pharmacol, Istanbul, Turkey | en_US |